glp-1 cancer risk Could medications help slow progression? A new Cleveland Clinic study found those taking GLP-1s were less likely to develop stage IV disease in several cancer types, when compared to patients Beat Weight Loss Plateaus: Sugar Craving packes:1

glp-1 cancer risk Could medications help slow progression? A new Cleveland Clinic study found those taking GLP-1s were less likely to develop stage IV disease in several cancer types, when compared to patients Beat Weight Loss Plateaus: Sugar Craving packes:1

Beat Weight Loss Plateaus: GLP-1 Alternatives That Actually Work

Food, fiber, and protein nudge the same hormone gently, with a smaller effect and no rebound

Sugar Craving

packes:1

E N D Presentation Transcript GLP-1 Agonists and Cardiovascular Health Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM Part 2 of 2 Change in Triglycerides and HDL-C as Function of Weight-Change Quartile at 82 Weeks Effects of GLP-1 agonists on inflammatory markers • GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) • E-selectin was not significantly reduced • C-reactive protein has also been associated with increased cardiovascular disease • Patients treated with exenatide showed marked decrease in c-reactive protein levels after an 82-week study (from 3.21mg/dL to 1.35 mg/dL) Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbAlc, and body weight in patients with type 2 diabetes mellitus